In an ovarian cancer trial, median survival was 14.7 months longer with added treatment

IMUNON, Inc. (Nasdaq: IMNN) announced new data from its Phase 2 OVATION 2 study, showing that IMNN-001 increased anti-tumoral T-cell activity in ovarian cancer patients. The treatment improved median overall survival by 14.7 months compared to standard care. The findings support the ongoing Phase 3 OVATION 3 trial. The data was presented at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting.

Original reporting
Published Nov 6, 2026, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 2:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$IMNN
Bullish
medium confidence
Mentioned
$IMNN
Relevance
7/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$IMNNBullishMed
01

Why it matters

Paired biopsy analysis from OVATION 2 provides an immunological mechanism for the previously reported survival improvement, reinforcing the rationale for OVATION 3 and potentially shifting perceived probability of success.

02

Market read

New translational biomarker evidence ties IMNN-001 to a tumor microenvironment shift and supports the clinical survival benefit narrative, which can influence biotech valuation and positioning ahead of pivotal Phase 3.

03

What to watch

The article does not provide new safety updates, subgroup efficacy, or Phase 3 readouts; investors may discount mechanistic data if systemic IL-12 exposure and long-term tolerability are not further quantified.

Relevance 7/10Novelty 6/10Timing: at SITC 2026 poster session, with OVATION 3 enrollment ongoing

Background

IMUNON’s IMNN-001 is an IL-12 DNA plasmid delivered intraperitoneally, studied in OVATION 2 with standard-of-care neoadjuvant and adjuvant chemotherapy, and now being advanced in pivotal OVATION 3.

Company-level read

Ticker impact

$IMNNBullishMedium confidence
Context

IMUNON reported translational Phase 2 OVATION 2 biopsy data showing IMNN-001 increased CD8+/Treg and CD8+/IDO+ ratios and tied it to a 14.7-month OS benefit.

Expected impact

Likely positive bias as investors price higher probability of OVATION 3 success based on consistent immune remodeling evidence.

Evidence & confidence

The article links serial paired biopsies to the previously reported OS improvement and emphasizes ongoing enrollment in the pivotal Phase 3 trial, which is a direct catalyst for biotech risk perception.

Market effects

Adds incremental evidence for DNA-mediated IL-12 delivery approaches in ovarian cancer immunotherapy, potentially supporting broader biotech sentiment in tumor microenvironment remodeling strategies.

Primarily US biotech sentiment given Nasdaq-listed issuer and US conference venue.

Moderate, as ovarian cancer immunotherapy translational findings can influence global clinical-investor narratives but are not a regulatory or approval event.

Counterpoint

Translational biomarkers may not fully de-risk efficacy; immune marker shifts can be supportive but still leave uncertainty around durability, generalizability, and Phase 3 endpoints.

Key entities

  • IMUNON, Inc.

    Clinical-stage biotech developing IMNN-001 DNA-mediated immunotherapy; reported OVATION 2 translational biopsy results and highlighted OVATION 3 enrollment.

  • IMNN-001

    IL-12 DNA plasmid vector in a nanoparticle delivery system intended for local IL-12 secretion and tumor microenvironment remodeling.

  • OVATION 2

    Randomized Phase 2 study in newly diagnosed advanced ovarian cancer evaluating IMNN-001 plus N/ACT versus N/ACT alone; included paired biopsies for translational analysis.

  • OVATION 3

    Pivotal Phase 3 trial currently enrolling to confirm safety and survival benefit of IMNN-001 plus chemotherapy versus chemotherapy alone.

Related articles

$IMNNMedAI 8/10

Imunon (IMNN) Q3 2026 Earnings Call Transcript

Imunon (IMNN) reported Q3 2026 progress, highlighting Phase III IMNN-001 study for ovarian cancer. The company saw strong enrollment, independent validation, and a partnership with the National Cancer Institute. IMNN-001 aims to address a disease with low survival rates and limited treatment advances. The company expects 50% enrollment by Q1 2028 and completion by Q1 2029, with interim analysis in Q1 2030.

$IMNNLow

Imunon 3Q 2026: EPS ($0.64) — 10-Q Summary

Imunon (IMNN) reported a wider net loss of $3.81M in Q3 2026, though diluted EPS improved to ($0.64) from ($1.16) YoY. Operating expenses decreased 1%, with R&D costs down 6%. The OVATION 3 trial enrollment exceeded expectations, and the company advanced its NCI collaboration and MRD study. Imunon discontinued PLACCINE and IMNN-101 development in Q1 2026.

$IMNNMed

Imunon Reports Q3 2026 Net Loss of $3.8 Million and Advances IMNN-001

Imunon reported a Q3 2026 net loss of $3.8M, or $0.64 per share, compared to $3.4M, or $1.16 per share, a year earlier. Operating expenses were $3.4M. The company updated its Phase 3 ovarian cancer study and other programs, with enrollment expected to complete by Q1 2029. Imunon also transferred ThermoDox rights to VoxelDox, contingent on funding.

$IMNNHighAI 8/10

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollm

$IMNNHighAI 8/10

IMUNON presents translational data from ovarian cancer trial

IMUNON Inc. (IMNN) presented data from its Phase 2 OVATION 2 study of IMNN-001 in advanced ovarian cancer, showing improved survival and immune response. The trial compared IMNN-001 with chemotherapy against chemotherapy alone. The company is now conducting a Phase 3 trial, OVATION 3, to confirm these results. IMNN-001 is a DNA-based immunotherapy targeting IL-12 delivery to tumor tissue.

$IMNNMedAI 8/10

Imunon (IMNN) Q2 2026 Earnings Call Transcript

Imunon (IMNN) held its Q2 2026 earnings call. Management reported Phase 2 OVATION II median overall survival of 45.1 months vs 30.4 months, and PARP maintenance survival of 65.6 vs 41.4 months. Q2 R&D was $1.5M, G&A $1.3M, net loss $2.8M. Cash was $6.9M after a $10M financing.